

Edgar Filing: SCIOS INC - Form 8-K

SCIOS INC
Form 8-K
August 13, 2001

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

Current Report
Pursuant to Section 13 or 15(d) of The

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 13, 2001

SCIOS, INC.

(Exact Name of Registrant as Specified in Charter)

Delaware

0-11749

95-3

(State or Other Jurisdiction of
Incorporation)

(Commission File Number)

(I.R.S. Employer

820 West Maude Avenue, Sunnyvale, CA 94086

(Address of Principal Executive Offices) (Zip Code)

(408) 616-8200

(Registrant's telephone number, including area code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

Item 5. Other Events.

On August 13, 2001, Scios Inc. announced that it has received final approval

Edgar Filing: SCIOS INC - Form 8-K

from the U.S. Food and Drug Administration (FDA) to market Natrecor(R) (nesiritide) for the intravenous treatment of patients with acutely decompensated congestive heart failure who have shortness of breath (i.e., dyspnea) at rest or with minimal activity. For additional information, refer to the press release attached as an exhibit to this Current Report on Form 8-K. The contents of the press release are incorporated by reference herein.

Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.

(c) Exhibits

The following exhibits are filed as part of this Report:

No.	Exhibit
---	-----
99.1	Press Release dated August 13, 2001

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SCIOS, INC.

By: /s/ David W. Gyska

David W. Gyska
Senior Vice President and
Chief Financial Officer

Date: August 13, 2001

3

EXHIBIT INDEX

No.	Exhibit
---	-----
99.1	Press Release dated August 13, 2001

